𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biomarkers for prostate cancer

✍ Scribed by Eddy S. Leman; Robert H. Getzenberg

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
86 KB
Volume
108
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The detection of prostate cancer using a blood test has by many standards changed the face of the disease. Despite this tremendous success, there are limitations attributed to the use of prostate specific antigen (PSA) as a means to screen and detect prostate cancer. PSA, as its name implies, is not specific for prostate cancer and as such is often found elevated in other prostatic diseases/symptoms associated with the aging male. Clearly, more specific marker(s) that could identify which individuals actually have prostate cancer and differentiate them from those without the disease would be of tremendous value. The search for more accurate and clinically useful biomarkers of prostate cancer has been extensive. This has focused on individual markers, as well as groups of markers. Included among these are PSA isoforms, pathological indicators and stains, nucleic acids and others. This article highlights the discovery of PSA as a first blood‐based biomarker for prostate cancer detection, as well as other molecular biomarkers and their potential application in detection of the disease. J. Cell. Biochem. 108: 3–9, 2009. Β© 2009 Wiley‐Liss, Inc.

πŸ“œ SIMILAR VOLUMES

Is sarcosine a biomarker for prostate ca
Is sarcosine a biomarker for prostate cancer?
✍ Haleem J. Issaq; Timothy D. Veenstra πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 55 KB

## Abstract Sarcosine was suggested in a letter to __Nature__ in 2009 as a biomarker for prostate cancer. This communication reviews what has been accomplished to date to determine whether sarcosine is or is not a biomarker for prostate cancer that can replace prostate‐specific antigen tests.

Nuclear matrix proteins as biomarkers in
Nuclear matrix proteins as biomarkers in prostate cancer
✍ Eddy S. Leman; Robert H. Getzenberg πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 116 KB

The nuclear matrix (NM) is the structural framework of the nucleus that consists of the peripheral lamins and pore complexes, an internal ribonucleic protein network, and residual nucleoli. The NM contains proteins that contribute to the preservation of nuclear shape and its organization. These prot

Use of multiple biomarkers for a molecul
Use of multiple biomarkers for a molecular diagnosis of prostate cancer
✍ Kelly A. Landers; Michelle J. Burger; Michelle A. Tebay; David M. Purdie; Betty πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 164 KB

## Abstract The identification of biomarkers capable of providing a reliable molecular diagnostic test for prostate cancer (PCa) is highly desirable clinically. We describe here 4 biomarkers, __UDP__‐__N__‐__Acetyl__‐α‐__D__‐__galactosamine transferase__ (__GalNAc__‐__T3__; not previously associate

GSTP1 CpG island hypermethylation as a m
GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer
✍ Masashi Nakayama; Mark L. Gonzalgo; Srinivasan Yegnasubramanian; Xiaohui Lin; An πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 295 KB

## Abstract Somatic hypermethylation of CpG island sequences at __GSTP1__, the gene encoding the π‐class glutathione S‐transferase, appears to be characteristic of human prostatic carcinogenesis. To consider the potential utility of this epigenetic alteration as a biomarker for prostate cancer, we

Prostate carcinoma tissue proteomics for
Prostate carcinoma tissue proteomics for biomarker discovery
✍ Yaxin Zheng; Ye Xu; Bin Ye; Junyi Lei; Michael H. Weinstein; Michael P. O'Leary; πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 249 KB

## Abstract ## BACKGROUND The advent of the prostate‐specific antigen (PSA) test has had a profound impact on the diagnosis and treatment of prostate carcinoma. However, the use of PSA levels alone for screening for prostate carcinoma was compromised by the variations in the amount of PSA produced